Mission Therapeutics

Mission Therapeutics describes itself as the world leader in deubiquitylating enzyme ('DUB') drug discovery and development, selectively targeting DUBs to treat diseases with high unmet medical need, including Parkinson's. The company states it has a rich pipeline of first-in-class therapeutics that selectively target specific disease-associated DUBs, including USP30, and that it has a collaborative, science-driven culture with strong links to key academic and research centres. Its lead candidates, MTX325 and MTX652, aim to inhibit USP30, a DUB which can retard the cellular quality control process called mitophagy. The company reports it was founded in 2011, has received £117 million in capital investment, and has explored 55 DUB targets.

Mission Therapeutics states it was founded in 2011. The company reports it has received £117 million in capital investment and has explored 55 DUB targets. It describes itself as the world leader in deubiquitylating enzyme ('DUB') drug discovery and development, selectively targeting DUBs to treat diseases including Parkinson's with high unmet medical need. Its lead candidates, MTX325 and MTX652, aim to inhibit USP30, a DUB which can retard the essential cellular quality control process called mitophagy. The company has attracted what it describes as one of the highest profile syndicates of investors in Europe, receiving £117 million in venture capital from a blue chip syndicate of institutional and corporate investors. It reports having divested MTX652, a Phase 2-ready asset, and announced a deal worth up to $292 million for Dimerix Ltd to develop the Acute Kidney Injury asset MTX652 while sharpening focus on its CNS pipeline.

World leader in deubiquitylating enzyme (DUB) drug discovery and development; first-in-class small molecule DUB inhibitors.

• MTX325

  Lead candidate aiming to inhibit USP30, a DUB which can retard mitophagy; a first-in-class Parkinson's disease candidate.

• MTX652

  Lead candidate aiming to inhibit USP30; a Phase 2-ready asset divested to Dimerix Ltd for development in Acute Kidney Injury.

1. 1Mission Therapeutics – Deubiquitylating enzymes: multiple drug opportunities across therapeutic areasmissiontherapeutics.com
2. 2About mission – Mission Therapeuticsmissiontherapeutics.com
3. 3Investors – Mission Therapeuticsmissiontherapeutics.com
4. 4Management Team – Mission Therapeuticsmissiontherapeutics.com
5. 5Mission Therapeutics (United Kingdom)wikidata.org